Advertisement

Cancer Causes & Control

, Volume 29, Issue 8, pp 785–791 | Cite as

Risk of diabetes complications among those with diabetes receiving androgen deprivation therapy for localized prostate cancer

  • Marie C. Bradley
  • Yingjun Zhou
  • Andrew N. Freedman
  • Marianne Ulcickas Yood
  • Charles P. Quesenbery
  • Reina Haque
  • Stephen K. Van Den Eeden
  • Andrea E. Cassidy-Bushrow
  • David Aaronson
  • Arnold L. Potosky
Original paper

Abstract

Purpose

Androgen deprivation therapy (ADT), used increasingly in the treatment of localized prostate cancer, is associated with substantial long-term adverse consequences, including incident diabetes. While previous studies have suggested that ADT negatively influences glycemic control in existing diabetes, its association with diabetes complications has not been investigated. In this study, we examined the association between ADT use and diabetes complications in prostate cancer patients.

Methods

A retrospective cohort study was conducted among men with newly diagnosed localized prostate cancer between 1995 and 2008, enrolled in three integrated health care systems. Men had radical prostatectomy or radiotherapy (curative intent therapy), existing type II diabetes mellitus (T2DM), and were followed through December 2010 (n = 5,336). Cox proportional hazards models were used to examine associations between ADT use and diabetes complications (any complication), and individual complications (diabetic neuropathy, diabetic retinopathy, diabetic amputation or diabetic cataract) after prostate cancer diagnosis.

Results

ADT use was associated with an increased risk of any diabetes complication after prostate cancer diagnosis (adjusted hazard ratio, AHR, 1.12, 95% CI 1.03–1.23) as well as an increased risk of each individual complication compared to non-use.

Conclusion

ADT use in men with T2DM, who received curative intent therapy for prostate cancer, was associated with an increased risk of diabetes complications. These findings support those of previous studies, which showed that ADT worsened diabetes control. Additional, larger studies are required to confirm these findings and to potentially inform the development of a risk-benefit assessment for men with existing T2DM, before initiating ADT.

Keywords

Androgen deprivation therapy Prostate cancer treatment Diabetes complications Adverse effects of cancer treatments Epidemiology 

Notes

Funding

Supported by Grants No. R01CA142934, RC1CA146238 and P30CA051008 from the National Cancer Institute.

Compliance with ethical standards

Conflict of interest

RH has received research funding from Novartis and AstraZeneca for studies unrelated to the present study. ACB received funding for a study from Novartis, which is unrelated to this study. SV received funding from GlaxoSmithKline for a project unrelated to this study. MB, AP, AF, MUY, XZ, DA, CPQ declare that they have no conflict of interest.

References

  1. 1.
    Cooperberg MR, Grossfeld GD, Lubeck DP et al (2003) National practice patterns and time trends in androgen ablation for localized prostate cancer. J Natl Cancer Inst 95(13):981–989CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Kawakami J, Cowan JE, Elkin EP et al (2006) Androgen-deprivation therapy as primary treatment for localized prostate cancer: data from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE). Cancer 106(8):1708–1714CrossRefPubMedGoogle Scholar
  3. 3.
    Keating NL, O’Malley AJ, McNaughton-Collins M et al (2008) Use of androgen deprivation therapy for metastatic prostate cancer in older men. BJU Int 101(9):1077–1083CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Zeliadt SB, Etzioni R, Ramsey SD et al (2007) Trends in treatment costs for localized prostate cancer: the healthy screenee effect. Med Care 45(2):154–159CrossRefPubMedGoogle Scholar
  5. 5.
    Alibhai SM, Duong-Hua M, Sutradhar R et al (2009) Impact of androgen deprivation therapy on cardiovascular disease and diabetes. J Clin Oncol 27(21):3452–3458CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Barry MJ, Delorenzo MA, Walker-Corkery ES et al (2006) The rising prevalence of androgen deprivation among older American men since the advent of prostate-specific antigen testing: a population-based cohort study. BJU Int 98(5):973–978CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    D’Amico AV, Denham JW, Crook J et al (2007) Influence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarctions. J Clin Oncol 25(17):2420–2425CrossRefPubMedGoogle Scholar
  8. 8.
    Keating NL, O’Malley AJ, Freedland SJ et al (2010) Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer. J Natl Cancer Inst 102(1):39–46CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Keating NL, O’Malley AJ, Smith MR (2006) Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol 24(27):4448–4456CrossRefPubMedGoogle Scholar
  10. 10.
    Moul JW, Banez LL, Freedland SJ (2007) Rising PSA in nonmetastatic prostate cancer. Oncology 21(12):1436–1445 1454.PubMedGoogle Scholar
  11. 11.
    Shahinian VB, Kuo YF, Freeman JL et al (2005) Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med 352(2):154–164CrossRefPubMedGoogle Scholar
  12. 12.
    Wei JT, Gross M, Jaffe CA et al (1999) Androgen deprivation therapy for prostate cancer results in significant loss of bone density. Urology 54(4):607–611CrossRefPubMedGoogle Scholar
  13. 13.
    Lu-Yao G, Stukel TA, Yao SL (2004) Changing patterns in competing causes of death in men with prostate cancer: a population based study. J Urol 171(6 Pt 1):2285–2290CrossRefPubMedGoogle Scholar
  14. 14.
    Smith MR, Lee H, Nathan DM (2006) Insulin sensitivity during combined androgen blockade for prostate cancer. J Clin Endocrinol Metab 91(4):1305–1308CrossRefPubMedGoogle Scholar
  15. 15.
    Lage MJ, Barber BL, Markus RA (2007) Association between androgen-deprivation therapy and incidence of diabetes among males with prostate cancer. Urology 70(6):1104–1108CrossRefPubMedGoogle Scholar
  16. 16.
    Tsai HK, D’Amico AV, Sadetsky N et al (2007) Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality. J Natl Cancer Inst 99(20):1516–1524CrossRefPubMedGoogle Scholar
  17. 17.
    Tsai HT, Keating NL, Van Den Eeden SK et al (2015) Risk of diabetes among patients receiving primary androgen deprivation therapy for clinically localized prostate cancer. J Urol 193(6):1956–1962CrossRefPubMedGoogle Scholar
  18. 18.
    US Food and Drug Administration. Review of GnRH agonists and notification to manufacturers of GnRH agonists to add new safety information to labeling regarding increased risk of diabetes and certain cardiovascular diseases, 2011. Available at: http://www.fda.gov/Drugs/DrugSafety/ucm229986.htm
  19. 19.
    Derweesh IH, Diblasio CJ, Kincade MC et al (2007) Risk of new-onset diabetes mellitus and worsening glycaemic variables for established diabetes in men undergoing androgen-deprivation therapy for prostate cancer. BJU Int 100(5):1060–1065PubMedGoogle Scholar
  20. 20.
    Haidar A, Yassin A, Saad F et al (2007) Effects of androgen deprivation on glycaemic control and on cardiovascular biochemical risk factors in men with advanced prostate cancer with diabetes. Aging Male 10(4):189–196CrossRefPubMedGoogle Scholar
  21. 21.
    Keating NL, Liu PH, O’Malley AJ et al (2014) Androgen-deprivation therapy and diabetes control among diabetic men with prostate cancer. Eur Urol 65(4):816–824CrossRefPubMedGoogle Scholar
  22. 22.
    Young BA, Lin E, Von Korff M et al (2008) Diabetes complications severity index and risk of mortality, hospitalization, and healthcare utilization. Am J Manag Care 14(1):15–23PubMedPubMedCentralGoogle Scholar
  23. 23.
    Centers for Disease Control. National Diabetes Statistics Report 2014 (2014) Department of Health and Human Services, Atlanta. https://www.cdc.gov/diabetes/pdfs/data/2014-report-estimates-of-diabetes-and-its-burden-in-the-united-states.pdf
  24. 24.
    Thompson I, Thrasher JB, Aus G et al (2007) Guideline for the management of clinically localized prostate cancer: 2007 update. J Urol 177(6):2106–2131CrossRefPubMedGoogle Scholar
  25. 25.
    Elixhauser A, Steiner C, Harris DR et al (1998) Comorbidity measures for use with administrative data. Med Care 36(1):8–27CrossRefPubMedGoogle Scholar
  26. 26.
    Shahani S, Braga-Basaria M, Basaria S (2008) Androgen deprivation therapy in prostate cancer and metabolic risk for atherosclerosis. J Clin Endocrinol Metab 93(6):2042–2049CrossRefPubMedGoogle Scholar
  27. 27.
    Allan CA, Collins VR, Frydenberg M et al (2014) Androgen deprivation therapy complications. Endocr Relat Cancer 21(4):T119-29CrossRefPubMedGoogle Scholar
  28. 28.
    King P, Peacock I, Donnelly R (1999) The UK prospective diabetes study (UKPDS): clinical and therapeutic implications for type 2 diabetes. Br J Clin Pharmacol 48(5):643–648CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Huang ES, Laiteerapong N, Liu JY et al (2014) Rates of complications and mortality in older patients with diabetes mellitus: the diabetes and aging study. JAMA Intern Med 174(2):251–258CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Cusick M, Meleth AD, Agron E et al (2005) Associations of mortality and diabetes complications in patients with type 1 and type 2 diabetes: early treatment diabetic retinopathy study report no. 27. Diabetes Care 28(3):617–625CrossRefPubMedGoogle Scholar
  31. 31.
    National Comprehensive Cancer Network. Practice Guidelines in Oncology, v.3.2012, Prostate cancer. http://www.nccn.org/professionals/physician_gls/PDF/prostate.pdf

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  • Marie C. Bradley
    • 1
  • Yingjun Zhou
    • 2
  • Andrew N. Freedman
    • 1
  • Marianne Ulcickas Yood
    • 3
  • Charles P. Quesenbery
    • 4
  • Reina Haque
    • 5
  • Stephen K. Van Den Eeden
    • 4
  • Andrea E. Cassidy-Bushrow
    • 6
  • David Aaronson
    • 7
  • Arnold L. Potosky
    • 2
  1. 1.Clinical and Translational Epidemiology Branch, Division of Cancer Control and Population SciencesNational Cancer InstituteRockvilleUSA
  2. 2.Georgetown University Lombardi Comprehensive Cancer CenterWashingtonUSA
  3. 3.Department of EpidemiologyBoston University School of Public HealthBostonUSA
  4. 4.Division of ResearchKaiser Permanente Northern CaliforniaOaklandUSA
  5. 5.Department of Research & EvaluationKaiser Permanente Southern CaliforniaPasadenaUSA
  6. 6.Department of Public Health SciencesHenry Ford Health SystemDetroitUSA
  7. 7.Kaiser Permanente, Oakland Medical CenterOaklandUSA

Personalised recommendations